Literature DB >> 22522912

Correlation analysis of clinical parameters with epigenetic modifications in the DUX4 promoter in FSHD.

Judit Balog1, Peter E Thijssen, Jessica C de Greef, Bharati Shah, Baziel G M van Engelen, Kyoko Yokomori, Stephen J Tapscott, Rabi Tawil, Silvère M van der Maarel.   

Abstract

The aim of our study was to identify relationships between epigenetic parameters correlating with a relaxed chromatin state of the DUX4 promoter region and clinical severity as measured by a clinical severity score or muscle pathologic changes in D4Z4 contraction-dependent (FSHD1) and -independent (FSHD2) facioscapulohumeral muscular dystrophy patients. Twenty primary fibroblast (5 control, 10 FSHD1 and 5 FSHD2) and 26 primary myoblast (9 control, 12 FSHD1 and 5 FSHD2) cultures originating from patients with FSHD and controls were analyzed. Histone modification levels were determined by chromatin immunoprecipitation. We examined correlations between the chromatin compaction score (ChCS) defined by the H3K9me3:H3K4me2 ratio and an age corrected clinical severity score (CSS) or muscle pathology score (MPS). Possible relationships were investigated using linear regression analysis and significance was tested by Pearson's product-moment coefficient.   We found a significant difference of the ChCS between controls and patients with FSHD1 and between controls and patients with FSHD2. Tissue specific differences in ChCS were also observed. We also found a near-significant relationship between ChCS and the age corrected CSS in fibroblasts but not in myoblasts. Surprisingly, we found a strong correlation between the MPS of the vastus lateralis and the CSS. Our results confirm the D4Z4 chromatin relaxation previously shown to be associated with FSHD in a small number of samples. A possible relationship between clinical and epigenetic parameters could be established in patient fibroblasts, but not in myoblasts. The strong correlation between the MPS of the vastus lateralis and the CSS suggests that this muscle can be used to study for surrogate markers of overall disease severity.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22522912      PMCID: PMC3398987          DOI: 10.4161/epi.20001

Source DB:  PubMed          Journal:  Epigenetics        ISSN: 1559-2294            Impact factor:   4.528


  14 in total

1.  Asymptomatic carriers and gender differences in facioscapulohumeral muscular dystrophy (FSHD).

Authors:  M M O Tonini; M R Passos-Bueno; A Cerqueira; S R Matioli; R Pavanello; M Zatz
Journal:  Neuromuscul Disord       Date:  2004-01       Impact factor: 4.296

2.  Hypomethylation of D4Z4 in 4q-linked and non-4q-linked facioscapulohumeral muscular dystrophy.

Authors:  Petra G M van Overveld; Richard J F L Lemmers; Lodewijk A Sandkuijl; Leo Enthoven; Sara T Winokur; Floor Bakels; George W Padberg; Gert-Jan B van Ommen; Rune R Frants; Silvère M van der Maarel
Journal:  Nat Genet       Date:  2003-11-23       Impact factor: 38.330

3.  Variable hypomethylation of D4Z4 in facioscapulohumeral muscular dystrophy.

Authors:  Petra G M van Overveld; Leo Enthoven; Enzo Ricci; Monica Rossi; Luciano Felicetti; Marc Jeanpierre; Sara T Winokur; Rune R Frants; George W Padberg; Silvère M van der Maarel
Journal:  Ann Neurol       Date:  2005-10       Impact factor: 10.422

4.  Protocol for the fast chromatin immunoprecipitation (ChIP) method.

Authors:  Joel D Nelson; Oleg Denisenko; Karol Bomsztyk
Journal:  Nat Protoc       Date:  2006       Impact factor: 13.491

5.  RNA transcripts, miRNA-sized fragments and proteins produced from D4Z4 units: new candidates for the pathophysiology of facioscapulohumeral dystrophy.

Authors:  Lauren Snider; Amy Asawachaicharn; Ashlee E Tyler; Linda N Geng; Lisa M Petek; Lisa Maves; Daniel G Miller; Richard J L F Lemmers; Sara T Winokur; Rabi Tawil; Silvère M van der Maarel; Galina N Filippova; Stephen J Tapscott
Journal:  Hum Mol Genet       Date:  2009-04-09       Impact factor: 6.150

6.  Evidence for anticipation and association of deletion size with severity in facioscapulohumeral muscular dystrophy. The FSH-DY Group.

Authors:  R Tawil; J Forrester; R C Griggs; J Mendell; J Kissel; M McDermott; W King; B Weiffenbach; D Figlewicz
Journal:  Ann Neurol       Date:  1996-06       Impact factor: 10.422

7.  Correlation between fragment size at D4F104S1 and age at onset or at wheelchair use, with a possible generational effect, accounts for much phenotypic variation in 4q35-facioscapulohumeral muscular dystrophy (FSHD)

Authors:  P W Lunt; P E Jardine; M C Koch; J Maynard; M Osborn; M Williams; P S Harper; M Upadhyaya
Journal:  Hum Mol Genet       Date:  1995-05       Impact factor: 6.150

8.  CD8(+) T cells in facioscapulohumeral muscular dystrophy patients with inflammatory features at muscle MRI.

Authors:  Giovanni Frisullo; Roberto Frusciante; Viviana Nociti; Giorgio Tasca; Rosaria Renna; Raffaele Iorio; Agata Katia Patanella; Elisabetta Iannaccone; Alessandro Marti; Monica Rossi; Assunta Bianco; Mauro Monforte; Pietro Attilio Tonali; Massimiliano Mirabella; Anna Paola Batocchi; Enzo Ricci
Journal:  J Clin Immunol       Date:  2010-11-10       Impact factor: 8.317

9.  Progress in the molecular diagnosis of facioscapulohumeral muscular dystrophy and correlation between the number of KpnI repeats at the 4q35 locus and clinical phenotype.

Authors:  E Ricci; G Galluzzi; G Deidda; S Cacurri; L Colantoni; B Merico; N Piazzo; S Servidei; E Vigneti; V Pasceri; G Silvestri; M Mirabella; F Mangiola; P Tonali; L Felicetti
Journal:  Ann Neurol       Date:  1999-06       Impact factor: 10.422

10.  Mapping and analysis of chromatin state dynamics in nine human cell types.

Authors:  Jason Ernst; Pouya Kheradpour; Tarjei S Mikkelsen; Noam Shoresh; Lucas D Ward; Charles B Epstein; Xiaolan Zhang; Li Wang; Robbyn Issner; Michael Coyne; Manching Ku; Timothy Durham; Manolis Kellis; Bradley E Bernstein
Journal:  Nature       Date:  2011-03-23       Impact factor: 49.962

View more
  34 in total

1.  The FSHD2 gene SMCHD1 is a modifier of disease severity in families affected by FSHD1.

Authors:  Sabrina Sacconi; Richard J L F Lemmers; Judit Balog; Patrick J van der Vliet; Pauline Lahaut; Merlijn P van Nieuwenhuizen; Kirsten R Straasheijm; Rashmie D Debipersad; Marianne Vos-Versteeg; Leonardo Salviati; Alberto Casarin; Elena Pegoraro; Rabi Tawil; Egbert Bakker; Stephen J Tapscott; Claude Desnuelle; Silvère M van der Maarel
Journal:  Am J Hum Genet       Date:  2013-09-26       Impact factor: 11.025

Review 2.  Facioscapulohumeral muscular dystrophy as a model for epigenetic regulation and disease.

Authors:  Charis L Himeda; Takako I Jones; Peter L Jones
Journal:  Antioxid Redox Signal       Date:  2014-12-04       Impact factor: 8.401

3.  Double SMCHD1 variants in FSHD2: the synergistic effect of two SMCHD1 variants on D4Z4 hypomethylation and disease penetrance in FSHD2.

Authors:  Marlinde L van den Boogaard; Richard J F L Lemmers; Pilar Camaño; Patrick J van der Vliet; Nicol Voermans; Baziel G M van Engelen; Adolfo Lopez de Munain; Stephen J Tapscott; Nienke van der Stoep; Rabi Tawil; Silvère M van der Maarel
Journal:  Eur J Hum Genet       Date:  2015-03-18       Impact factor: 4.246

Review 4.  Facioscapulohumeral muscular dystrophy (FSHD) molecular diagnosis: from traditional technology to the NGS era.

Authors:  Stefania Zampatti; Luca Colantoni; Claudia Strafella; Rosaria Maria Galota; Valerio Caputo; Giulia Campoli; Giulia Pagliaroli; Stefania Carboni; Julia Mela; Cristina Peconi; Stefano Gambardella; Raffaella Cascella; Emiliano Giardina
Journal:  Neurogenetics       Date:  2019-03-25       Impact factor: 2.660

5.  Premature termination codons in the DMD gene cause reduced local mRNA synthesis.

Authors:  Raquel García-Rodríguez; Monika Hiller; Laura Jiménez-Gracia; Zarah van der Pal; Judit Balog; Kevin Adamzek; Annemieke Aartsma-Rus; Pietro Spitali
Journal:  Proc Natl Acad Sci U S A       Date:  2020-07-02       Impact factor: 11.205

6.  Dynamic transcriptomic analysis reveals suppression of PGC1α/ERRα drives perturbed myogenesis in facioscapulohumeral muscular dystrophy.

Authors:  Christopher R S Banerji; Maryna Panamarova; Johanna Pruller; Nicolas Figeac; Husam Hebaishi; Efthymios Fidanis; Alka Saxena; Julian Contet; Sabrina Sacconi; Simone Severini; Peter S Zammit
Journal:  Hum Mol Genet       Date:  2019-04-15       Impact factor: 6.150

7.  A novel molecular mechanism in human genetic disease: a DNA repeat-derived lncRNA.

Authors:  Daphne S Cabianca; Valentina Casa; Davide Gabellini
Journal:  RNA Biol       Date:  2012-10-01       Impact factor: 4.652

8.  Inter-individual differences in CpG methylation at D4Z4 correlate with clinical variability in FSHD1 and FSHD2.

Authors:  Richard J L F Lemmers; Jelle J Goeman; Patrick J van der Vliet; Merlijn P van Nieuwenhuizen; Judit Balog; Marianne Vos-Versteeg; Pilar Camano; Maria Antonia Ramos Arroyo; Ivonne Jerico; Mark T Rogers; Daniel G Miller; Meena Upadhyaya; Jan J G M Verschuuren; Adolfo Lopez de Munain Arregui; Baziel G M van Engelen; George W Padberg; Sabrina Sacconi; Rabi Tawil; Stephen J Tapscott; Bert Bakker; Silvère M van der Maarel
Journal:  Hum Mol Genet       Date:  2014-09-25       Impact factor: 6.150

9.  DUX4-induced gene expression is the major molecular signature in FSHD skeletal muscle.

Authors:  Zizhen Yao; Lauren Snider; Judit Balog; Richard J L F Lemmers; Silvère M Van Der Maarel; Rabi Tawil; Stephen J Tapscott
Journal:  Hum Mol Genet       Date:  2014-05-26       Impact factor: 6.150

10.  Mesodermal iPSC-derived progenitor cells functionally regenerate cardiac and skeletal muscle.

Authors:  Mattia Quattrocelli; Melissa Swinnen; Giorgia Giacomazzi; Jordi Camps; Ines Barthélemy; Gabriele Ceccarelli; Ellen Caluwé; Hanne Grosemans; Lieven Thorrez; Gloria Pelizzo; Manja Muijtjens; Catherine M Verfaillie; Stephane Blot; Stefan Janssens; Maurilio Sampaolesi
Journal:  J Clin Invest       Date:  2015-11-16       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.